LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-08-31
Case ID: NM_000051.4_c.5503del_20260831_171220
Framework: ACMG/AMP 2015
Variant classification summary

NM_000051.4:c.5503del

ATM  · NP_000042.3:p.(Thr1835LeufsTer11)  · NM_000051.4
GRCh37: chr11:108175404 GA>G  ·  GRCh38: chr11:108304677 GA>G
Gene: ATM Transcript: NM_000051.4
Final call
Pathogenic
PVS1 very strong PM2 supporting PM5 supporting
All criteria require review: For research and educational purposes only.
Gene
ATM
Transcript
NM_000051.4
Protein
NP_000042.3:p.(Thr1835LeufsTer11)
gnomAD AF
ClinVar
Pathogenic
OncoKB
Likely Oncogenic
Interpretation summary
Generated evidence synthesis
1
PVS1 (Very Strong): frameshift p.(Thr1835LeufsTer11) is predicted to trigger nonsense-mediated decay and removes the critical FAT/PI3K/FATC domain.
2
PM2 (Supporting): absent from gnomAD v4.1 (AF=0), below the VCEP <=0.001% threshold, corroborated by gnomAD v2.1 and gnomAD-Canada.
3
PM5 (Supporting): truncating variant with premature stop upstream of the VCEP cutoff residue p.Arg3047.
4
Final classification: Pathogenic, produced by the VCEP combination rule (one very strong plus at least two supporting criteria).
Final determination: ClinGen HBOP ATM VCEP v1.5 (cspec doc 639508985) Rule4: 1 Very Strong (PVS1) plus >=2 Supporting criteria (PM2_Supporting, PM5_Supporting) combines to Pathogenic.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 Met Met at very strong: frameshift p.(Thr1835LeufsTer11) is predicted to trigger nonsense-mediated decay and removes the critical FAT/PI3K/FATC domain.
cspec vcep_atm_pvs1_1_5 pvs1_gene_context pvs1_variant_assessment pvs1_generic_framework gnomad_v2 gnomad_v4
PS1 N/A Not applicable: PS1 applies only to missense changes, and this variant is a frameshift.
cspec spliceai
PS2 N/A Not applicable: the ATM VCEP forbids de novo criteria for this gene, and no de novo occurrence was reported.
cspec
PS3 Not assessed Not assessed: no validated functional assay result for this variant was available.
cspec vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1 vcep_suppl_tables1_pmid_40580951
PS4 Not assessed Not assessed: no case-control enrichment data for this variant was available.
cspec PMID:25394175
PM1 N/A Not applicable: the ATM VCEP marks PM1 unused, and this is a frameshift rather than a missense variant.
cspec
PM2 Met Met at supporting: absent from gnomAD v4.1 (AF=0), below the VCEP <=0.001% threshold.
cspec gnomad_v4 gnomad_v2 gnomad_canada
PM3 Not assessed Not assessed: no affected-proband genotype, in-trans second allele, or phase evidence was available.
cspec vcep_atm_pm3_bp2_1_5
PM4 N/A Not applicable: PM4 is reserved for stop-loss variants; this frameshift creates a premature stop, already captured by PVS1.
cspec
PM5 Met Met at supporting: truncating variant with premature stop upstream of the VCEP cutoff residue p.Arg3047.
cspec pm5_candidates
PM6 N/A Not applicable: the ATM VCEP forbids assumed-de-novo criteria, and none was reported.
cspec
PP1 Not assessed Not assessed: no segregation data in affected relatives was available for this variant.
cspec
PP2 N/A Not applicable: PP2 is a missense-oriented criterion and does not apply to a truncating variant.
cspec
PP3 N/A Not applicable: PP3 applies to missense or splice-relevant variants, not to this coding frameshift.
cspec spliceai
PP4 N/A Not applicable: the ATM VCEP marks PP4 as unused.
cspec
PP5 Not assessed Not assessed: no expert-panel ClinVar assertion exists; the single laboratory submission is not expert-panel evidence.
clinvar
BA1 Not met Not met: absent from gnomAD v4.1 (AF=0), below the >0.5% BA1 population-frequency threshold.
cspec gnomad_v4 gnomad_v2 gnomad_canada
BS1 Not met Not met: absent from gnomAD v4.1 (AF=0), below the >0.05% BS1 population-frequency threshold.
cspec gnomad_v4 gnomad_v2 gnomad_canada
BS2 N/A Not applicable: the ATM VCEP marks BS2 as unused for ATM.
cspec
BS3 Not assessed Not assessed: no validated functional evidence of normal protein function was available.
cspec vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1 vcep_suppl_tables1_pmid_40580951
BS4 N/A Not applicable: the ATM VCEP forbids lack-of-co-segregation evidence for this gene.
cspec
BP1 N/A Not applicable: BP1 targets missense variants, not premature truncating changes.
cspec
BP2 Not assessed Not assessed: no unaffected-carrier co-occurrence, phase, or homozygosity evidence was available.
cspec vcep_atm_pm3_bp2_1_5
BP3 N/A Not applicable: BP3 targets in-frame indels in nonfunctional repeats; this is a frameshift in a constitutive exon.
cspec
BP4 N/A Not applicable: BP4 targets missense or synonymous/intronic variants; this is a coding frameshift.
cspec spliceai
BP5 N/A Not applicable: the ATM VCEP marks BP5 as unused.
cspec
BP6 Not assessed Not assessed: no expert-panel benign ClinVar assertion exists for this variant.
clinvar
BP7 N/A Not applicable: BP7 targets synonymous or deep-intronic variants; this is a coding frameshift.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.